Liquidia Technologies, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on the stock and has a $54.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight the potential of Liquidia Technologies’ product, Yutrepia. The recent data presented at the CHEST Annual Meeting in Chicago provided further evidence of Yutrepia’s efficacy and safety in treating patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study showed that a significant percentage of patients maintained or improved their six-minute walk distance, with a noteworthy portion achieving substantial gains, which underscores the drug’s potential benefits.
Additionally, the expanded dataset from the interim data confirmed consistent improvements in a new cardiac effort endpoint, reinforcing the strong product profile of Yutrepia. This positions the drug as a promising therapy for patients with PAH and PH-ILD, especially in the new-patient segment of the PH-ILD market. Furthermore, the potential market opportunity is bolstered by the upside surprise from Tyvaso nebulizer switches, indicating a sizeable patient pool that Yutrepia could capture. These factors collectively support the Buy rating for Liquidia Technologies’ stock.
In another report released on October 17, Wells Fargo also maintained a Buy rating on the stock with a $31.00 price target.